The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London pre-open: Footsie to recoup losses

Tue, 18th Aug 2009 07:44

Footsie is expected to win back some of the heavy losses it posted yesterday.British Land saw the value of its property portfolio fall to £8.18bn in the first quarter but said the pace of decline has slowed markedly. The group, which has been the subject of intense bid speculation, said £3.2bn (39%) of assets either increased (£1.7bn) or are unchanged (£1.5bn) in value since March 2009.Cash strapped miner Rio Tinto has received a $2.025bn offer for the majority of its Alcan Packaging business. The binding offer has been received from Amcor and covers the Alcan Packaging global pharmaceuticals, global tobacco, food Europe and food Asia divisions. The deal does not include the remaining Beaty packaging division which will be sold off separately.A joint venture including support services firm Carillion has won a 'Building Schools for the Future' contract for Durham. The Local Education Partnership (LEP), comprising Carilliom, Durham County Council and Building Schools for the Future Investments LLP, will deliver more than 40 schools in four phases over a 10-year contract period under the terms of the £500m programme.Car dealer Pendragon reported sharply lower profits in the six months to June 30 as recession-hit motorists held onto their old cars rather than splashing out on new ones. It posted a pre-tax profit of £11.4m, compared with £21.1m over the same period the previous year, as revenue slid to £1.59bn from £2.48bn.Respiratory inhaler firm Vectura remains "very confident" about prospects with important drug trials due to start later this year and plenty of cash in the bank. Phase III trials of QVA149 to treat chronic obstructive pulmonary disease are expected to start in late 2009. The drug combines Vectura's NVA237 and indacaterol (QAB149), developed by Swiss group Novartis.Online video services provider Amino Technologies posted an operating loss compared with a profit the same time a year before as challenging economic conditions continued hit the group. The group reported an operating loss before exceptional items of £3.10m for the six months ended 31 May 2009 compared with an operating profit £0.61m before.Nightclub owner Luminar can breathe a little easier on news that 95.5% of the shares available through an open offer have been taken up and buyers have been found for the remainder. The group raised £37.5m (£35.7m net) from a firm placing and open offer at 95p a share. Just 920,000 of the 19.4m shares available through the open offer were unwanted by shareholders.
More News
19 Mar 2021 09:46

BROKER RATINGS: Barclays and Goldman Sachs downgrade Hammerson

BROKER RATINGS: Barclays and Goldman Sachs downgrade Hammerson

Read more
18 Mar 2021 10:36

Vectura shares rise on swing to profit, GBP115 million special payout

Vectura shares rise on swing to profit, GBP115 million special payout

Read more
18 Mar 2021 07:43

Royalty income, litigation win see Vectura beat expectations

(Sharecast News) - Vectura reported a 6.9% improvement in its total revenue on Thursday, to £190.6m, driven by development services and a surge in income from royalties.

Read more
11 Mar 2021 16:13

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
5 Mar 2021 12:29

Vectura delays results because of KPMG staff shortage

(Sharecast News) - Vectura delayed the publication of its annual results after KPMG asked for more time to audit the accounts because of a staff shortage caused by Covid-19.

Read more
2 Mar 2021 16:01

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
22 Jan 2021 09:32

LONDON BROKER RATINGS SUMMARY: Deutsche Bank Ups British Land, Landsec

LONDON BROKER RATINGS SUMMARY: Deutsche Bank Ups British Land, Landsec

Read more
12 Jan 2021 10:13

Vectura Forecasts 2020 Earnings To Top Board Expectations

Vectura Forecasts 2020 Earnings To Top Board Expectations

Read more
12 Jan 2021 08:16

Vectura reports 'strong' operational performance in 2020

(Sharecast News) - Inhaled medicines-focussed pharmaceutical company Vectura Group updated the market on its trading on Tuesday, saying it expected revenue and adjusted EBITDA for 2020 to be ahead of board expectations, following the fourth quarter approval of VR315 (US), or generic 'Advair', alongside Hikma.

Read more
30 Dec 2020 19:10

UK EXECUTIVE CHANGE SUMMARY: Nutrition Firm Director Joins Tate & Lyle

UK EXECUTIVE CHANGE SUMMARY: Nutrition Firm Director Joins Tate & Lyle

Read more
29 Dec 2020 12:04

Vectura Says Glaxo Will Not Appeal Award In Ellipta Litigation

Vectura Says Glaxo Will Not Appeal Award In Ellipta Litigation

Read more
29 Dec 2020 10:04

Glaxo not seeking re-hearing in Ellipta litigation, says Vectura

(Sharecast News) - Vectura said on Tuesday that GlaxoSmithKline has not sought to petition the US Court of Appeals for a re-hearing in the companies' ongoing litigation over GSK's Ellipta inhalers.

Read more
18 Dec 2020 17:08

LONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal

LONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal

Read more
18 Dec 2020 12:08

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

Read more
18 Dec 2020 10:45

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.